How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.
Keep Reading
A closer look at how reading, conversation, and AI are being combined
Updated
February 7, 2026 2:18 PM
Assorted plush character toys piled inside a glass claw machine. PHOTO: ADOBE STOCK
In the past, “educational toys” usually meant flashcards, prerecorded stories or apps that asked children to tap a screen. ChooChoo takes a different approach. It is designed not to instruct children at them, but to talk with them.
ChooChoo is an AI-powered interactive reading companion built for children aged three to six. Instead of playing stories passively, it engages kids in conversation while reading. It asks questions, reacts to answers, introduces new words in context and adjusts the story flow based on how the child responds. The goal is not entertainment alone, but language development through dialogue.
That idea is rooted in research, not novelty. ChooChoo is inspired by dialogic reading methods from Yale’s early childhood language development work, which show that children learn language faster when stories become two-way conversations rather than one-way narration. Used consistently, this approach has been shown to improve vocabulary, comprehension and confidence within weeks.
The project was created by Dr. Diana Zhu, who holds a PhD from Yale and focused her work on how children acquire language. Her aim with ChooChoo was to turn academic insight into something practical and warm enough to live in a child’s room. The result is a device that listens, responds and adapts instead of simply playing content on command.
What makes this possible is not just AI, but where that AI runs.
Unlike many smart toys that rely heavily on the cloud, ChooChoo is built on RiseLink’s edge AI platform. That means much of the intelligence happens directly on the device itself rather than being sent back and forth to remote servers. This design choice has three major implications.
First, it reduces delay. Conversations feel natural because the toy can respond almost instantly. Second, it lowers power consumption, allowing the device to stay “always on” without draining the battery quickly. Third, it improves privacy. Sensitive interactions are processed locally instead of being continuously streamed online.
RiseLink’s hardware, including its ultra-low-power AI system-on-chip designs, is already used at large scale in consumer electronics. The company ships hundreds of millions of connected chips every year and works with global brands like LG, Samsung, Midea and Hisense. In ChooChoo’s case, that same industrial-grade reliability is being applied to a child’s learning environment.
The result is a toy that behaves less like a gadget and more like a conversational partner. It engages children in back-and-forth discussion during stories, introduces new vocabulary in natural context, pays attention to comprehension and emotional language and adjusts its pace and tone based on each child’s interests and progress. Parents can also view progress through an optional app that shows what words their child has learned and how the system is adjusting over time.
What matters here is not that ChooChoo is “smart,” but that it reflects a shift in how technology enters early education. Instead of replacing teachers or parents, tools like this are designed to support human interaction by modeling it. The emphasis is on listening, responding and encouraging curiosity rather than testing or drilling.
That same philosophy is starting to shape the future of companion robots more broadly. As edge AI improves and hardware becomes smaller and more energy efficient, we are likely to see more devices that live alongside people instead of in front of them. Not just toys, but helpers, tutors and assistants that operate quietly in the background, responding when needed and staying out of the way when not.
In that sense, ChooChoo is less about novelty and more about direction. It shows what happens when AI is designed not for spectacle, but for presence. Not for control, but for conversation.
If companion robots become part of daily life in the coming years, their success may depend less on how powerful they are and more on how well they understand when to speak, when to listen and how to grow with the people who use them.